BriaCell Therapeutics Corp Ordinary Shares BCTX 深 沪
等待开盘 12-16 09:30:00 美东时间
9.2427
-0.297
-3.12%
华盛通- 最 高9.78
- 今 开9.78
- 成交量 2.36万股
- 最 低 9.06
- 昨 收 9.54
- 总市值 6262.95万
- 52周最高 98.20
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 6.00
- 委 比 -19.76%
- 总股本 677.61万
- 历史最高 1860.5799
- 量 比 0.38
- 振 幅 7.55%
- 历史最低 9.06
- 每 手 1
- 风险率 23.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Braze Inc (NYSE:BRZE) rose sharply in pre-market trading after the co...
12-10 18:00
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
BriaCell Therapeutics Corp. reported that its Phase 3 study for metastatic breast cancer (MBC) has screened over 230 patients and enrolled over 160. Enrollment is progressing well, with strong interest from clinical sites and patients. Topline interim data is expected in 1H2026, and the trial continues under FDA Fast Track designation. The study evaluates Bria-IMT plus an immune checkpoint inhibitor versus physician’s choice in advanced MBC. Posi...
12-09 12:30
BriaCell Therapeutics To Present Phase 2 Survival, And Phase 3 Biomarker Data Across Three Clinical Posters At 2025 SABCS
Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus positive key
12-02 20:39
BriaCell Therapeutics To Highlight Phase 2 Safety And Efficacy Signals And Biomarker Findings In Both Phase 2 And Pivotal Phase 3 Studies At 2025 SABCS
Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2 and the pivotal
11-25 20:37
BriaCell Therapeutics To Present Three Clinical, One Preclinical Posters At 2025 San Antonio Breast Cancer Symposium
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that
11-18 20:32
BriaCell To Present Preclinical Data On Next-Gen Cancer Vaccine Platform At SITC 2025
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to
11-04 20:36
BriaCell Partners with MSK to Advance Cancer Immunotherapy
BriaCell Therapeutics ( ($TSE:BCT) ) just unveiled an update. BriaCell Therapeu...
10-21 20:11
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
BriaCell Therapeutics Corp. collaborates with Memorial Sloan Kettering Cancer Center’s Therapeutics Accelerator Program to accelerate clinical development of Bria-OTS+, a next-generation personalized off-the-shelf immunotherapy targeting metastatic breast cancer, prostate cancer, and other cancers. The partnership includes manufacturing, IND development, and clinical support for Bria-BRES+, BriaCell’s breast cancer therapy. MSK’s expertise will h...
10-21 11:30
BriaCell Therapeutics Announces Clinical Biomarker Data In Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus An Immune CPI In Metastatic Breast Cancer
Biomarkers identified in BriaCell's Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC)No new safety or tolerability issues
10-20 19:33
BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025
BriaCell Therapeutics reports encouraging Phase 3 clinical data for Bria-IMT in metastatic breast cancer, showing similar biomarker trends as in the Phase 2 study and no new safety concerns. PFS data highlights Neutrophil to Lymphocyte Ratio (NLR) as a potential biomarker, with better outcomes for patients with NLR 0.7–2.3. The Phase 3 study remains blinded, with interim OS analysis planned upon 144 patient events.
10-20 11:30
